Pet Dog Monepantel Trial: Participating Clinics and Inclusion/Exclusion Criteria

The monepantel (MPL) treatment naive B cell lymphoma clinical trial program is transitioning from Phase 2 to Phase 3. Finalisation of dosing optimisation is underway, including investigating MPL in combination either with prednisolone or CHOP-based protocols[1]. The trial involves treatment at home with a consultation at the dog’s nearest trial centre, as listed below. Basic Inclusion and Exclusion criteria are also listed below. Trial centre veterinarians will provide greater detail about enrolment and the nature of the trial.

[1] L- asparaginase, vincristine, cyclophosphamide, prednisolone, and doxorubicin

Participating MPL Trial Centres

Dr Sonya Yu
Animal Referral Hospital,
Homebush, Sydney NSW
tel: (02) 9758 8666

 

Dr Kathleen O’Connell
Animal Referral Hospital,
Sinnamon Park, Brisbane QLD
Tel: (07) 3172 0593

 

Dr Sue Bennett
Western Australian Veterinary Emergency and Specialty (WAVES),
Success, Perth WA
Tel: (08) 9412 5700

 

Dr Jessica Finlay
Perth Veterinary Specialists,
Osborne Park, Perth WA
Tel: (08) 9204 0400

Basics of Inclusion Criteria

• Dogs of any sex, at least one year of age, with B cell nodal lymphoma
• No other significant intercurrent disease
• No previous medication for the lymphoma
• WHO stage 1-5, substage a.
• Modified Karnofsky performance score 0 or 1

Basics of Exclusion Criteria

• Dogs that have received prior treatment for lymphoma
• Any corticosteroid use in preceding 8 weeks
• Puppies less than 1 year old
• Lactating or pregnant bitches
• Dogs used for breeding
• Modified Karnofsky performance score 2 or above

One of the dogs on trial (left) going camping with his friend.

[1] L- asparaginase, vincristine, cyclophosphamide, prednisolone, and doxorubicin